Breaks Categories: News

ThursdayMay 19, 2022 11:37 am

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Announces Milestone in Psilocybin Study on Parkinson’s Patients

Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that, in conjunction with the University of California San Francisco (“UCSF”), researchers have successfully dosed patients suffering from Parkinson’s disease. As part of the study, researchers are collecting blood samples to determine the effects of psilocybin on inflammatory markers of patients who have exhibited signs of Parkinson’s. “Successful dosing and collection of blood samples from enrolled patients is an important milestone that demonstrates the progress being made in this study, which seeks to examine the effects of psilocybin as an anti-inflammatory…

Continue Reading

WednesdayMay 18, 2022 12:31 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) CEO Featured in Bell2Bell Podcast Episode

Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, and its founder and CEO Eric Weisblum are the center of attention in the most recent episode of the Bell2Bell Podcast. The Bell2Bell Podcast is designed to provide informative updates and exclusive interviews with executives operating in fast-moving industries. During the interview, hosted by Stuart Smith, Weisblum talks about his own background and experience in the industry as well as Silo Pharma’s business model and the company’s recent milestones. Weisman has been building and managing businesses for more than two decades and has…

Continue Reading

WednesdayMay 18, 2022 12:15 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO to Share Expansion Strategy at H.C. Wainwright Conference

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today shared details regarding participation of its CEO Matt Stang at the H.C. Wainwright Annual Global Life Sciences Conference taking place May 23-26, 2022, in Miami, Florida. The four-day event will feature keynote presentations, investor one-on-one meetings, networking opportunities and evening entertainment. At this year's conference, Stang will present the company's expansion strategy and participate in one-on-one meetings. Interested parties should visit https://ibn.fm/UGjjp to register for the event. To view the full press release, visit https://ibn.fm/EkzBY About Delic Holdings Corp. Delic…

Continue Reading

TuesdayMay 17, 2022 2:01 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Participation in May 18 NYSE Trading Bell Ceremony

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the morning trading bell ceremony at the New York Stock Exchange on May 18, 2022. The first psychedelics company to be listed on the NYSE, Cybin started trading on the exchange in August 2021. In addition, Cybin announced that management team members will be hosting in-person meetings with institutional investors in New York City on May 18–19. “We are delighted to be part of this ceremony as we celebrate the innovation that Cybin is bringing to the challenges of mental health treatments…

Continue Reading

MondayMay 16, 2022 2:37 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Issues Update on Default Status

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, announced that it is providing a default status report; the report is being released in accordance with the alternative information guidelines set out in National Policy 12-203 — Management Cease Trade Orders (“NP 12-203”). According to the announcement, Delic is experiencing delays to its audit, which means that the required annual financial statements and management's discussion and analysis for FY 2021 have been delayed as well. The company had requested that a management cease trade order (“MCTO”) be imposed as a result…

Continue Reading

ThursdayMay 12, 2022 12:29 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC Enters New VA Partnership in Arizona

Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), today announced a new partnership with the Veterans Administration (“VA”) in Arizona. Per the update, veterans suffering from treatment-resistant depression, PTSD and anxiety will have access to ketamine therapy at KWC Arizona clinics located in Phoenix, Tucson and Mesa - Gilbert at no out-of-pocket cost with prior authorization from the VA. This new VA partnership is in addition to the one established with the Burnsville, Minnesota-based KWC. “At KWC, we take great pride in supporting our…

Continue Reading

WednesdayMay 11, 2022 11:18 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright Global Investment Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its CEO Doug Drysdale will participate in a fireside chat at the H.C. Wainwright Global Investment Hybrid Conference. The event is taking place May 23-26, 2022, at the Fontainebleau Miami Beach. Drysdale’s fireside chat will be webcast live at 12:30 p.m. ET on Wednesday, May 25. Interested parties should visit https://ibn.fm/0nlvQ to register and access the live webcast. An archived version of the webcast will also be available on the company’s investor relations website. To view the full press release, visit https://ibn.fm/34DNj…

Continue Reading

WednesdayMay 11, 2022 11:10 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Featured in InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, has closed the sale of non-core assets for $16.4 million. This news and additional information about the company was featured in an InvestmentPitch Media video, available for viewing on InvestmentPitch and YouTube or by visiting www.InvestmentPitch.com and entering “FSD Pharma” in the search box. Anthony Durkacz, interim CEO and co-executive chairman of FSD Pharma, said of the move: “This is a major accomplishment and puts us in a good position going forward especially considering the current state…

Continue Reading

TuesdayMay 10, 2022 2:29 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Kernel Share Preliminary Results from Flow Feasibility Study

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its partner Kernel, are reporting preliminary data that confirm the ability of Kernel’s quantitative neuroimaging technology, Flow, to successfully measure neuro-effect of ketamine. Kernel is a leader in noninvasive neuroimaging. According to the announcement, results of a Cybin-sponsored feasibility study indicate that ketamine-induced changes in functional connectivity continued for several days after administration. Specifically, Kernel Flow successfully measured the neuro-effect of ketamine over 11 days (baseline at Days 1-5, dosing at Day 6, follow-up at Days 7-11); in addition, the results confirmed changes in functional…

Continue Reading

TuesdayMay 10, 2022 2:09 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Closes CAD$16.4M Sale of Non-Core Assets

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the closing of the sale of the company’s former cannabis processing facility located in Cobourg, Ontario, Canada, for gross proceeds of CAD$16,400,000 in cash. “This is a major accomplishment and puts us in a good position going forward especially considering the current state of the capital markets. While most companies have taken huge write-downs on dispositions of cannabis-related assets, we were able to net significant profit from selling the facility,” said Anthony Durkacz, interim CEO…

Continue Reading